Coherus Oncology (CHRS) Times Interest Earned (2016 - 2025)
Coherus Oncology (CHRS) has disclosed Times Interest Earned for 13 consecutive years, with -$20.4 as the latest value for Q4 2025.
- Quarterly Times Interest Earned fell 135.77% to -$20.4 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.12 through Dec 2025, down 430.27% year-over-year, with the annual reading at -$20.12 for FY2025, 377.55% down from the prior year.
- Times Interest Earned hit -$20.4 in Q4 2025 for Coherus Oncology, down from -$19.07 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $57.03 in Q4 2024 to a low of -$29.63 in Q1 2021.
- Historically, Times Interest Earned has averaged -$8.49 across 5 years, with a median of -$8.0 in 2022.
- Biggest five-year swings in Times Interest Earned: crashed 902.12% in 2021 and later soared 978.85% in 2024.
- Year by year, Times Interest Earned stood at -$6.83 in 2021, then rose by 19.63% to -$5.49 in 2022, then decreased by 18.26% to -$6.49 in 2023, then skyrocketed by 978.85% to $57.03 in 2024, then tumbled by 135.77% to -$20.4 in 2025.
- Business Quant data shows Times Interest Earned for CHRS at -$20.4 in Q4 2025, -$19.07 in Q3 2025, and -$19.98 in Q2 2025.